Mechanism of TangGanJian on nonalcoholic fatty liver disease with type 2 diabetes mellitus

Abstract

Context: TangGanJian (TGJ) has a curative effect in the clinical treatment of nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes mellitus (T2DM), while the mechanism involved in the treatment process remains unclear.

Objective: This study details the mechanism of TGJ on the treatment of NAFLD with T2DM.

Materials and methods: NAFLD was induced in T2DM rat model. Male Wistar rats were assigned into six groups: Group I (control), Group II (model), Group III (pioglitazone, 0.5 mg/kg), Group IV (high dose of TGJ, 24.8 g/kg), Group V (middle dose of TGJ, 12.4 g/kg) and Group VI (low dose of TGJ, 6.2 g/kg). All rats in each group were treated with the corresponding drugs by gavage for 8 weeks. Haematoxylin and eosin analysis was conducted. The indicators of inflammatory and oxidative stress were analysed utilizing one-way ANOVA.

Results: The contents of TNF-α (15.794 ± 3.302 pg/mL), IL-6 (76.801 ± 8.491 pg/mL), IL-1β (100.101 ± 13.150 pg/mL), CRP (1.052 ± 0.079 pg/mL) and MDA (3.972 ± 0.159 pg/mL) were obviously elevated in NAFLD with T2DM rats compared to controls. Except for the IL-6, the levels of other markers declined in a dose-dependent manner after treatment with TGJ. The SOD (14.139 ± 1.479 U/mgprot) and GSH-PX (81.511 ± 5.276 U/mgprot) levels significantly decreased in NAFLD with T2DM rats, while the levels of these indicators increased after treatment with TGJ.

Conclusions: TGJ may be a therapy for the NAFLD with T2DM rats by modulating the inflammatory response and the oxidative stress capacity.

Keywords: GSH-PX; SOD; TNF-α; Therapy; inflammation; oxidative stress.

Figure 1.

Appearance of the liver (A) and haematoxylin and eosin (H&E) analysis (B). I: control; II: model; III: pioglitazone; IV: high dose of TangGanJian (TGJ: 24.8 g/kg); V: middle dose of TGJ (12.4 g/kg); VI: low dose of TGJ (6.2 g/kg).